Searching for a Potential Algorithm for Clostridium difficile Testing at a Tertiary Care Hospital: Does Toxin Enzyme...

Area of Science:

• Clinical Microbiology
• Infectious Diseases
• Diagnostic Accuracy

Background:

• Clostridium difficile infections (CDI) are a significant cause of illness and death.
• Diagnostic methods for CDI include molecular tests, enzyme immunoassays (EIAs) for toxins, and culture.
• Debate exists regarding the sensitivity of molecular tests and their impact on clinical decision-making.

Purpose of the Study:

• To determine if clinical factors correlate with C. difficile toxin status.
• To assess if toxin status information can guide clinical management and reduce overtreatment.
• To evaluate the utility of combining molecular (PCR) and EIA toxin testing.

Main Methods:

• Retrospective analysis of 201 PCR-positive C. difficile stool samples from adult patients.
• Samples were tested for toxin using EIA.
• Clinical and laboratory data were collected and analyzed.

Main Results:

• 47% of PCR-positive samples were also EIA-positive; 53% were EIA-negative.
• Patients with both PCR and EIA positive results were more likely to have a history of CDI (P=0.015).
• No significant differences in clinical parameters were found between EIA-positive and EIA-negative groups.

Conclusions:

• Combining PCR and EIA testing for C. difficile does not appear to change clinical management at this institution.
• Clinical factors did not consistently correlate with EIA toxin results.
• Current diagnostic strategies are adequate for managing patients with suspected CDI.